Food and Drug Administration Flags Water System Violations at World Perfumes Inc

In a Warning Letter to World Perfumes Inc., the Food and Drug Administration cited major deficiencies in a water system used to manufacture oral and topical drugs, referencing violations of 21 CFR 211.63 and 21 CFR 211.100.

The FDA criticized system design flaws, particularly “dead legs” that allow stagnant water and potential biofilm formation, increasing contamination risks and hindering proper sanitization. The agency also faulted inadequate monitoring for objectionable microorganisms, including Burkholderia cepacia complex.

Additionally, the company used alternative microbiological testing methods without proper validation. Trend data generated from these unvalidated methods was rejected. The FDA requires proof that such methods are equivalent to pharmacopeial standards.

The agency called for an independent system assessment, a remediation and monitoring plan, a comprehensive risk evaluation of distributed batches, and full validation documentation, underscoring increased regulatory scrutiny of pharmaceutical water systems.

26-02-2026